NANO Nanobiotix SA

Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Regulatory News:

(Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2022, on Wednesday, September 28, 2022, after the close of the US market.

The announcement will be followed by a conference call and live audio webcast on Thursday, September 29, 2022, at 8:00 AM ET / 2:00 PM CET. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review the Company’s half-year results and provide an update on business activities before taking questions from participants.

A live webcast of the call may be accessed by visiting the investors section of the company's website at . Participants may register for the call . They will be able to join the call via dial-in or one-click dial-out. It is recommended to join 10 minutes prior the event start.

Participants are invited to email their questions in advance to .

A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy-activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at or follow us on and .

EN
22/09/2022

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

Free Trial
NANO NANOBIOTIX SA

Nanobiotix: 1 director

A director at Nanobiotix bought 10,780 shares at 3.415EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

2h / 14m 2h / 14m 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor ...

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 3:45 pm EDT / 9:45 pm CESTLocation: New York, NYPresenter...

14h / 44m 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX participera à la conférence investisseurs annuelle Jefferie...

NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global Healthcare PARIS et CAMBRIDGE, Mass., 28 mai 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui que Nanobiotix participera à une discussion (« fireside chat ») à la conférence suivante : Conférence Jefferies Global HealthcareDate : jeu...

14h / 44m 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Nanobiotix Provides First Quarter 2025 Operational and Financial Updat...

Nanobiotix Provides First Quarter 2025 Operational and Financial Update Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lung Cancer Conference in a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) in locoregional recurrent NSCLC and a Phase 1 study of JNJ-1900 (NBTXR3) in combination with nivolumab or pembrolizumab for patients with lung metastases from NSCLC or other solid tumorsStrengthened financial position through an amendment to th...

May 21, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Nanobiotix fait le point sur sa trésorerie et son activité opérationne...

Nanobiotix fait le point sur sa trésorerie et son activité opérationnelle du premier trimestre 2025 Traitement du premier patient dans l’étude CONVERGE, un essai clinique contrôlé randomisé de Phase 2 chez des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) non résécable de stade 3.Présentation de données à l’ELCC (European Lung Cancer Conference, conférence européenne sur le cancer du poumon) d’une étude de Phase 1 de ré-irradiation avec JNJ-1900 (NBTXR3) dans le CPNPC récurrent locorégional et une étude de Phase 1 avec JNJ-1900 (NBTXR3) en association avec nivoluma...

May 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch